Synonym
Hydroflumethiazide; Diuredemina; Glomerulin; Hidroflumetiazid; Diurometon; Flutizide;
IUPAC/Chemical Name
1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide
InChi Key
DMDGGSIALPNSEE-UHFFFAOYSA-N
InChi Code
InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)
SMILES Code
C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
331.29
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ogola EN, Yonga GO. Comparative study of the efficacy and tolerability of
hydroflumethiazide versus propranolol in Africans with mild to moderate
hypertension. East Afr Med J. 1993 May;70(5):277-9. PubMed PMID: 8306902.
2: Agrawal YK, Giridhar R, Menon SK. Spectrophotometric determination of
hydroflumethiazide. J Pharm Biomed Anal. 1989;7(6):759-63. PubMed PMID: 2490778.
3: Hermansen K, Schmitz O, Mogensen CE. Effects of a thiazide diuretic
(hydroflumethiazide) and a loop diuretic (bumetanide) on the endocrine pancreas:
studies in vitro. Metabolism. 1985 Aug;34(8):784-9. PubMed PMID: 2862565.
4: Corrigan OI, Holohan EM. Amorphous spray-dried
hydroflumethiazide-polyvinylpyrrolidone systems: physiochemical properties. J
Pharm Pharmacol. 1984 Apr;36(4):217-21. PubMed PMID: 6144766.
5: Brørs O, Braut GS, Braut S, Jacobsen S. Interaction of hydroflumethiazide and
2,4-disulfamyl-5-trifluoromethylaniline with cyclic AMP phosphodiesterase and
carbonic anhydrase. Acta Pharmacol Toxicol (Copenh). 1982 Oct;51(4):273-7. PubMed
PMID: 6295063.
6: Brørs O, Jacobsen S. Distribution of elimination of hydroflumethiazide in man.
Eur J Clin Pharmacol. 1979 Sep;16(2):125-31. PubMed PMID: 499309.
7: Brørs O, Jacobsen S. Pharmacokinetics of hydroflumethiazide during repeated
oral administration to healthy subjects. Eur J Clin Pharmacol. 1979 May
21;15(4):281-6. PubMed PMID: 477713.
8: McNamara PJ, Colburn WA, Gibaldi M. Absorption kinetics of hydroflumethiazide.
J Clin Pharmacol. 1978 Apr;18(4):190-3. PubMed PMID: 632365.
9: Owen BJ, Wilkie SV. Separation and quantitative determination of
2,4-disulfamyl-5-trifluoromethylaniline in hydroflumethiazide using high-pressure
liquid chromatography. J Pharm Sci. 1977 Jun;66(6):877-8. PubMed PMID: 874795.
10: Smith RB, Smith RV, Yakatan GJ. Spectrofluorometric determination of
hydroflumethiazide in plasma and urine. J Pharm Sci. 1976 Aug;65(8):1208-11.
PubMed PMID: 10417.
11: Corrigan OI, Timoney RF. Anomalous behavior of some hydroflumethiazide
crystal samples. J Pharm Pharmacol. 1974 Oct;26(10):838-40. PubMed PMID: 4156551.
12: Kjaerulff J, Lyngsoe J. [The antihypertensive effects of bendroflumethiazide,
hydroflumethiazide, trichlormethiazide, chlorthalidone and furosemide]. Ugeskr
Laeger. 1973 Aug 13;135(33):1744-6. Danish. PubMed PMID: 4777951.
13: Agren A, Bäck T. Complex formation between macromolecules and drugs. 8.
Binding of saccharine, N-methyl saccharine, and the diuretic drugs
hydroflumethiazide and bendroflumethiazide to human serum albumin. Acta Pharm
Suec. 1973 Jun;10(3):223-8. PubMed PMID: 4729699.
14: Nishioeda Y. [Effect of hydroflumethiazide on the kinetics of thyroxine in
the blood]. Nihon Naibunpi Gakkai Zasshi. 1972 Jul 20;48(4):245-59. Japanese.
PubMed PMID: 4626614.
15: A spironolactone-hydroflumethiazide combination in hypertension.
Practitioner. 1971 Mar;206(233):412-5. PubMed PMID: 4929196.
16: Jamil MA. A comparative study of spironolactone and hydroflumethiazide alone
and together in the treatment of hypertension. Guys Hosp Rep. 1971;120(3):207-19.
PubMed PMID: 4951058.
17: Williamson JM, Neilson FJ, Gibbs WN. Hypoplastic anaemia and
hydroflumethiazide. Scott Med J. 1966 Jan;11(1):19-20. PubMed PMID: 5905311.
18: PISANI E, BOSELLI G. [Clinical research with a new diuretic:
hydroflumethiazide potassium salt]. Minerva Med. 1962 Oct 24;53:3159-62. Italian.
PubMed PMID: 13943783.
19: VERTES V, KATZ JB, ROBINOW SH. Comparison of short term metabolic effects of
hydroflumethiazide and hydrochlorothiazide. J Chronic Dis. 1962 Feb;15:171-7.
PubMed PMID: 13925585.
20: GILLHESPY RO. The antihypertensive activity of hydroflumethiazide with
Rauwolfia. J Ir Med Assoc. 1962 Feb;50:49-50. PubMed PMID: 13898651.
